Pathogenicity of Antibodies against NMDA Receptor: Molecular Insights into Autoimmune Psychosis.
Trends in Neurosciences. 2018-08-01; 41(8): 502-511
DOI: 10.1016/j.tins.2018.05.002
Read on PubMed
Jézéquel J(1), Johansson EM(1), Leboyer M(2), Groc L(3).
Author information:
(1)Université de Bordeaux, Interdisciplinary Institute for Neuroscience, UMR 5297, Bordeaux, France; CNRS, IINS UMR 5297, Bordeaux, France.
(2)University Paris Est Créteil, Psychiatry Department, Hopitaux Universitaires Henri Mondor, AP-HP, DHU PePSY, INSERM, U955, Créteil, France.
(3)Université de Bordeaux, Interdisciplinary Institute for Neuroscience, UMR 5297, Bordeaux, France; CNRS, IINS UMR 5297, Bordeaux, France.
Recent years have seen a flourishing literature on detection of circulating
autoantibodies against neurotransmitter receptors in patients with
neuropsychiatric disorders. These studies have generated hope for a better
understanding of the underlying molecular dysfunctions and for appropriate
therapeutic strategies. However, the detection of these autoantibodies in healthy
subjects, and the lack of mechanistic insights have fostered debate about the
pathogenic role of such autoantibodies. Here, we specifically discuss the
biological evidence linking autoantibodies directed against the glutamatergic
N-methyl-d-aspartate (NMDA) receptor (NMDAR-Abs) and psychosis, emphasising
recent single-molecule imaging investigations that unveiled the impaired surface
trafficking of NMDAR in the presence of NMDAR-Abs from psychotic patients.
Although still in its infancy, the hypothesis that NMDAR-Abs from patients with
psychosis play a pathogenic role is thus gaining support, opening avenues of
fundamental and translational investigations.
Copyright © 2018 Elsevier Ltd. All rights reserved.
DOI: 10.1016/j.tins.2018.05.002
PMID: 29807730 [Indexed for MEDLINE]